Supplementary table 1. Characteristics of patients treated with FOLFIRINOX and with other chemotherapy regimens.

| Characteristic                              | FOLFIRINOX (N = 35) | Other regimens (N = 139) | p     |
|---------------------------------------------|----------------------|--------------------------|-------|
| Age (years)                                 | 68 (66.5-70.5)       | 73 (70.0-77.0)           | <0.001|
| Median (Range)                              |                      |                          |       |
| Sex                                         | 24 (68.6)            | 64 (46.0)                | 0.022 |
| Male                                        | 11 (31.4)            | 75 (54.0)                |       |
| Female                                      |                      |                          |       |
| Age-adjusted Charlson Comorbidity Score     | 9 (8-10)             | 10 (9-10)                | <0.001|
| Median (IQR)                                |                      |                          |       |
| Polypharmacy                                | 11 (31.4)            | 70 (50.3)                | 0.08  |
| Yes                                         | 24 (68.6)            | 65 (46.7)                |       |
| No                                          | 0 (0.0)              | 4 (2.9)                  |       |
| Unknown                                     |                      |                          |       |
| ECOG                                        | 31 (88.5)            | 92 (66.2)                | 0.039 |
| 0-1                                         | 4 (11.5)             | 47 (33.8)                |       |
| 2-3                                         |                      |                          |       |
| Primary tumor location                      | 16 (45.7)            | 92 (66.2)                | 0.057 |
| Head, neck or uncinate process              | 19 (54.2)            | 46 (33.1)                |       |
| Body or tail                                | 0 (0.0)              | 1 (0.7)                  |       |
| Unknown                                     |                      |                          |       |
| Number of metastatic sites                  | 1 (1-2)              | 1 (1-2)                  | 0.90  |
| Median (Range)                              |                      |                          |       |
| CA 19-9 (U/ml)                              | 1,587.0 (107.5-9,594.5) | 495.0 (59.3-2,448.0) | 0.12  |
Supplementary Table 2. Overall survival of patients treated with different chemotherapy regimens according to age at diagnosis, AACCS, and ECOG.

| Characteristic | FOLFIRINOX N = 35 | FOLFOX/FOLFIRI N = 48 | Gemcitabine N = 77 |
|---------------|-------------------|----------------------|--------------------|
| Age (years)   |                   |                      |                    |
| 65-79         | 16.9 (8.4-35.1)   | 6.9 (1.6-19.7)       | 10.6 (3.7-NA)      |
| 70-74         | 12.9 (8.5-NA)     | 6.5 (2.8-12.1)       | 7.8 (3.4-11.2)     |
| ≥ 75          | 15.5 (2.9-NA)     | 7.1 (4.0-9.0)        | 5.4 (4.3-9.9)      |
| AACCS ≤ 9     | 16.9 (8.8-35.1)   | 7.2 (4.9-9.3)        | 6.7 (4.0-11.2)     |
| < 9           | 13.1 (1.6-NA)     | 6.5 (4.8-8.0)        | 7.3 (4.5-10.1)     |
| ECOG 0        | 35.1 (9.2-NA)     | 8.2 (1.7-24.2)       | 15.1 (3.1-NA)      |
| 1             | 13.1 (8.5-16.9)   | 7.3 (4.9-9.3)        | 8.2 (4.7-11.2)     |
| 2-3           | 2.65 (0.6-NA)     | 5.6 (4.0-7.2)        | 5.2 (3.6-7.0)      |
| Survival (months) | p | Survival (months) | p | Survival (months) | p |
| 0.58          | 0.41              | 0.55                 |
| 0.002         | 0.24              | 0.01                 |

Supplementary Table 3. Further lines of treatment in the group of patients treated with FOLFIRINOX and in the group of patients treated with other regimens.

| Further lines of treatment | All patients that received chemotherapy (N = 174) | FOLFIRINOX (N = 35) | Other regimens (N = 139) | p |
|----------------------------|--------------------------------------------------|---------------------|-------------------------|---|
| Second-line                | 72 (41.3)                                        | 21 (60.0)           | 51 (36.6)               | 0.020 |
| Third-line                 | 26 (14.9)                                        | 8 (22.8)            | 18 (12.9)               | 0.182 |
| Fourth-line and beyond     | 6 (3.4)                                          | 1 (2.9)             | 5 (3.5)                 | 1.000 |